Envestnet Asset Management Inc. Sells 2,218 Shares of DaVita Inc. (NYSE:DVA)

Envestnet Asset Management Inc. decreased its stake in shares of DaVita Inc. (NYSE:DVA) by 2.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 106,111 shares of the company’s stock after selling 2,218 shares during the period. Envestnet Asset Management Inc. owned approximately 0.12% of DaVita worth $14,704,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in DVA. Norges Bank bought a new stake in shares of DaVita during the fourth quarter worth $36,626,000. Corient Private Wealth LLC boosted its holdings in DaVita by 546.9% during the fourth quarter. Corient Private Wealth LLC now owns 27,977 shares of the company’s stock worth $2,931,000 after purchasing an additional 23,652 shares during the last quarter. Quest Partners LLC acquired a new position in DaVita during the fourth quarter worth $74,000. Franklin Resources Inc. boosted its holdings in DaVita by 42.0% during the fourth quarter. Franklin Resources Inc. now owns 7,866 shares of the company’s stock worth $824,000 after purchasing an additional 2,325 shares during the last quarter. Finally, Advisory Services Network LLC acquired a new position in DaVita during the fourth quarter worth $385,000. Institutional investors own 90.12% of the company’s stock.

DaVita Price Performance

Shares of DVA opened at $161.57 on Wednesday. The firm has a market capitalization of $14.17 billion, a PE ratio of 18.36, a PEG ratio of 0.95 and a beta of 0.87. The company’s 50-day moving average is $148.63 and its 200-day moving average is $141.60. DaVita Inc. has a fifty-two week low of $71.51 and a fifty-two week high of $166.04. The company has a debt-to-equity ratio of 9.94, a current ratio of 1.16 and a quick ratio of 1.12.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.47 by $0.12. The company had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.15 billion. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The company’s revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the firm earned $2.08 earnings per share. Equities analysts forecast that DaVita Inc. will post 9.99 EPS for the current year.

Insider Activity

In other news, CEO Javier Rodriguez sold 32,176 shares of the stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $155.93, for a total value of $5,017,203.68. Following the transaction, the chief executive officer now directly owns 905,659 shares of the company’s stock, valued at $141,219,407.87. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Kathleen Alyce Waters sold 7,857 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the transaction, the insider now directly owns 83,011 shares of the company’s stock, valued at $12,137,038.31. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Javier Rodriguez sold 32,176 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $155.93, for a total transaction of $5,017,203.68. Following the transaction, the chief executive officer now directly owns 905,659 shares in the company, valued at $141,219,407.87. The disclosure for this sale can be found here. Insiders have sold 173,482 shares of company stock valued at $27,387,069 over the last ninety days. 2.00% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

DVA has been the subject of several recent research reports. Bank of America increased their target price on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a report on Wednesday, August 7th. TD Cowen increased their price target on shares of DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research note on Wednesday, July 24th. StockNews.com cut shares of DaVita from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 8th. Truist Financial increased their price target on shares of DaVita from $150.00 to $165.00 and gave the company a “hold” rating in a research note on Tuesday, August 20th. Finally, UBS Group increased their price target on shares of DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, DaVita currently has a consensus rating of “Hold” and a consensus target price of $157.00.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.